BSE Live
Sep 29, 16:01Prev. Close
5425.95
Open Price
5408.00
Bid Price (Qty.)
5380.00 (18)
Offer Price (Qty.)
5540.00 (9)
NSE Live
Sep 29, 15:57Prev. Close
5433.00
Open Price
5400.00
Bid Price (Qty.)
5409.00 (447)
Offer Price (Qty.)
0.00 (0)
Balance Sheet of Alkem Laboratories (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
EQUITIES AND LIABILITIES | ||||||
SHAREHOLDER'S FUNDS | ||||||
Equity Share Capital | 23.91 | 23.91 | 23.91 | 23.91 | 23.91 | |
Total Share Capital | 23.91 | 23.91 | 23.91 | 23.91 | 23.91 | |
Reserves and Surplus | 12,297.92 | 10,530.70 | 9,325.94 | 8,719.75 | 7,601.84 | |
Total Reserves and Surplus | 12,297.92 | 10,530.70 | 9,325.94 | 8,719.75 | 7,601.84 | |
Total Shareholders Funds | 12,321.83 | 10,554.61 | 9,349.85 | 8,743.66 | 7,625.75 | |
NON-CURRENT LIABILITIES | ||||||
Long Term Borrowings | 0.00 | 0.00 | 0.00 | 0.00 | 6.32 | |
Deferred Tax Liabilities [Net] | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Other Long Term Liabilities | 149.85 | 131.21 | 52.37 | 44.12 | 40.30 | |
Long Term Provisions | 263.89 | 245.58 | 284.17 | 257.63 | 190.42 | |
Total Non-Current Liabilities | 413.74 | 376.79 | 336.54 | 301.75 | 237.04 | |
CURRENT LIABILITIES | ||||||
Short Term Borrowings | 371.24 | 957.23 | 1,125.89 | 2,245.52 | 1,332.84 | |
Trade Payables | 1,463.78 | 1,570.94 | 1,076.34 | 1,111.02 | 952.92 | |
Other Current Liabilities | 889.32 | 467.59 | 626.66 | 573.20 | 430.53 | |
Short Term Provisions | 135.69 | 110.64 | 215.94 | 194.02 | 193.65 | |
Total Current Liabilities | 2,860.03 | 3,106.40 | 3,044.83 | 4,123.76 | 2,909.94 | |
Total Capital And Liabilities | 15,595.60 | 14,037.80 | 12,731.22 | 13,169.17 | 10,772.73 | |
ASSETS | ||||||
NON-CURRENT ASSETS | ||||||
Tangible Assets | 1,563.92 | 1,747.63 | 1,768.51 | 1,731.22 | 1,648.60 | |
Intangible Assets | 27.42 | 34.61 | 56.58 | 150.85 | 109.76 | |
Capital Work-In-Progress | 45.82 | 49.93 | 185.10 | 232.45 | 323.26 | |
Other Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Fixed Assets | 1,667.84 | 1,873.02 | 2,053.84 | 2,114.52 | 2,081.62 | |
Non-Current Investments | 3,751.54 | 2,685.22 | 2,692.96 | 2,393.45 | 1,990.21 | |
Deferred Tax Assets [Net] | 1,429.14 | 1,286.66 | 1,084.92 | 1,048.74 | 954.43 | |
Long Term Loans And Advances | 9.07 | 0.35 | 8.34 | 17.85 | 33.32 | |
Other Non-Current Assets | 389.94 | 152.47 | 118.95 | 734.00 | 81.61 | |
Total Non-Current Assets | 7,247.53 | 5,997.72 | 5,959.01 | 6,308.56 | 5,141.19 | |
CURRENT ASSETS | ||||||
Current Investments | 655.24 | 143.76 | 312.59 | 135.16 | 162.17 | |
Inventories | 1,522.90 | 1,849.56 | 1,724.66 | 1,975.73 | 1,513.26 | |
Trade Receivables | 1,559.84 | 1,753.64 | 1,768.34 | 1,768.22 | 1,556.55 | |
Cash And Cash Equivalents | 1,056.11 | 1,065.85 | 2,163.87 | 2,297.21 | 1,673.36 | |
Short Term Loans And Advances | 1.65 | 3.95 | 1.68 | 14.53 | 21.11 | |
OtherCurrentAssets | 3,552.33 | 3,223.32 | 801.07 | 669.76 | 705.09 | |
Total Current Assets | 8,348.07 | 8,040.08 | 6,772.21 | 6,860.61 | 5,631.54 | |
Total Assets | 15,595.60 | 14,037.80 | 12,731.22 | 13,169.17 | 10,772.73 | |
OTHER ADDITIONAL INFORMATION | ||||||
CONTINGENT LIABILITIES, COMMITMENTS | ||||||
Contingent Liabilities | 1,071.66 | 124.49 | 323.65 | 359.22 | 376.65 | |
CIF VALUE OF IMPORTS | ||||||
Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Stores, Spares And Loose Tools | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Trade/Other Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Capital Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
EXPENDITURE IN FOREIGN EXCHANGE | ||||||
Expenditure In Foreign Currency | 354.81 | 541.29 | 418.95 | 391.06 | 246.74 | |
REMITTANCES IN FOREIGN CURRENCIES FOR DIVIDENDS | ||||||
Dividend Remittance In Foreign Currency | -- | -- | -- | -- | -- | |
EARNINGS IN FOREIGN EXCHANGE | ||||||
FOB Value Of Goods | -- | -- | -- | -- | -- | |
Other Earnings | 2,539.87 | 2,031.60 | 1,691.63 | 1,992.36 | 1,955.49 | |
BONUS DETAILS | ||||||
Bonus Equity Share Capital | 11.96 | 11.96 | 11.96 | 11.96 | 11.96 | |
NON-CURRENT INVESTMENTS | ||||||
Non-Current Investments Quoted Market Value | -- | 15.63 | 15.63 | -- | -- | |
Non-Current Investments Unquoted Book Value | 712.39 | 119.33 | 27.07 | 235.16 | 92.34 | |
CURRENT INVESTMENTS | ||||||
Current Investments Quoted Market Value | 580.54 | 41.69 | 207.52 | -- | -- | |
Current Investments Unquoted Book Value | 74.70 | 102.07 | 105.07 | -- | 129.64 |
29.09.2025
23.09.2025
19.09.2025
10.09.2025
Alkem Lab Standalone June 2025 Net Sales at Rs 2,372.17 crore, down 5.12% Y-o-Y
10.09.2025
Alkem Lab Standalone June 2025 Net Sales at Rs 2,372.17 crore, down 5.12% Y-o-Y
12.08.2025
Q1 Results impact: Alkem Labs, PN Gadgil shares rally up to 10% on strong earnings, Granules up 4%
12.06.2025
Alkem Lab Standalone March 2025 Net Sales at Rs 2,044.94 crore, down 13.55% Y-o-Y
05.06.2025
Alkem Lab Consolidated March 2025 Net Sales at Rs 3,143.75 crore, up 7.08% Y-o-Y
12.07.2023
Alkem Laboratories Q1 PAT seen up 135.1% YoY to Rs 299.7 cr: Nirmal Bang
17.10.2018
Alkem Labs Q2 PAT may dip 30.2% YoY to Rs. 220 cr: HDFC Securities
20.04.2018
Alkem Labs Q4 PAT may dip 1.5% YoY to Rs. 130 cr: HDFC Securities
12.04.2018
Pharma Q4 earnings preview: Tough quarter; US pricing pressure, domestic sales recovery hold key